Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford and its Clinical BioManufacturing Facility have approached MHRA in order to receive feedback, guidance and support in the development and manufacture of a candidate vaccine for treatment of malaria that has seen them explore an innovative approach to viral vectors using a chimpanzee virus.